{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {},
    "annotation_url": {
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
    },
    "document_metadata": {
      "authors": "Esther Wollert, Sandra Spalek",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "Screening of a neuronal cell model of Tau pathology for therapeutic compounds",
      "version": "1.0.1"
    },
    "namespace_pattern": {
      "PUBCHEM": "^\\d+$"
    },
    "namespace_url": {
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/501ceccdc9a27d97edbdc48a89ebe8e1dd3626e9/export/conso-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/hgnc.genefamily-names.belns"
    },
    "path": "tau/pickhardt2018.bel",
    "pybel_version": "0.14.10"
  },
  "links": [
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "As shown before, Tau aggregation (on the level of oligomeric and/or fibril aggregates) is toxic for cells.",
      "key": "4f0681432e878def62787098a5039848",
      "line": 79,
      "relation": "increases",
      "source": 0,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "The dose response screening identified compounds related to the inhibition of 3 major targets led to inhibition of Tau aggregation: p38 MAPK (7 out of 8 compounds in the initial library), VEGFR1/2 (3 of 8) and TGF (3 of 10). ",
      "key": "7a00c6ab0d8f5be6b18ef6f6ec4aec54",
      "line": 87,
      "relation": "increases",
      "source": 54,
      "subject": {
        "modifier": "Activity"
      },
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "4513f38a01f9719097cefe21e2dee9c7",
      "line": 207,
      "relation": "association",
      "source": 54,
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "6f9e75c6d4d24b8d92dc2b6690d6f89f",
      "line": 208,
      "relation": "association",
      "source": 54,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "07ce716d0a29b982f9a3f97c123c580b",
      "line": 220,
      "relation": "association",
      "source": 54,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "The dose response screening identified compounds related to the inhibition of 3 major targets led to inhibition of Tau aggregation: p38 MAPK (7 out of 8 compounds in the initial library), VEGFR1/2 (3 of 8) and TGF (3 of 10). ",
      "key": "295f8770221820c4de861ec329a4af02",
      "line": 88,
      "relation": "increases",
      "source": 44,
      "subject": {
        "modifier": "Activity"
      },
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "The dose response screening identified compounds related to the inhibition of 3 major targets led to inhibition of Tau aggregation: p38 MAPK (7 out of 8 compounds in the initial library), VEGFR1/2 (3 of 8) and TGF (3 of 10). ",
      "key": "16327dd1eac60204b61a550e281f3fa1",
      "line": 89,
      "relation": "increases",
      "source": 52,
      "subject": {
        "modifier": "Activity"
      },
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "65a12831fe65c9a4d5c001ecd23d534f",
      "line": 202,
      "relation": "association",
      "source": 52,
      "target": 3
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "e1e01a77e37bf48a0d506d2761193753",
      "line": 204,
      "relation": "association",
      "source": 52,
      "target": 4
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "The dose response screening identified compounds related to the inhibition of 3 major targets led to inhibition of Tau aggregation: p38 MAPK (7 out of 8 compounds in the initial library), VEGFR1/2 (3 of 8) and TGF (3 of 10). ",
      "key": "a0dc48fc715b40f3ce9f6355491bf2dd",
      "line": 90,
      "relation": "increases",
      "source": 39,
      "subject": {
        "modifier": "Activity"
      },
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": " Conversely, compounds related to HDAC inhibition (16 of 20) led to enhanced Tau aggregation, suggesting that HDAC activity is important for suppressing aggregation",
      "key": "4aaf2ee978ee866e0d69a824bcf5265b",
      "line": 97,
      "relation": "decreases",
      "source": 36,
      "subject": {
        "modifier": "Activity"
      },
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "672701cd63e555d1a7ac2eff38c7a005",
      "line": 185,
      "relation": "association",
      "source": 36,
      "target": 28
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Treatment with Givinostat (1.2 µM) lead to a nearly 7-fold increase in the fraction of ThS + cells (from ~ 12% to ~ 84%, Fig. S4A and B, blue lines) compared to the uninduced control, and 2.5-fold compared to the induced control. ",
      "key": "56715f2e1a351a4b782b36cdee72cfa0",
      "line": 106,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 26,
      "target": 36
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Treatment with Givinostat (1.2 µM) lead to a nearly 7-fold increase in the fraction of ThS + cells (from ~ 12% to ~ 84%, Fig. S4A and B, blue lines) compared to the uninduced control, and 2.5-fold compared to the induced control. ",
      "key": "c8058dd74fe672ffd4f089885c8c93d3",
      "line": 107,
      "relation": "increases",
      "source": 26,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "d2925406870d31966b57f9a3ce0ed08c",
      "line": 155,
      "relation": "increases",
      "source": 28,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "10cb72addb9fa4d90bb8a57ac33d50bc",
      "line": 185,
      "relation": "association",
      "source": 28,
      "target": 36
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "6330e1c61133244ea98115f23778175f",
      "line": 156,
      "relation": "increases",
      "source": 11,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "428d78e56c1e632e99c20bc8b600d699",
      "line": 186,
      "relation": "association",
      "source": 11,
      "target": 48
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "98b878f70e956c344591dd5d8db67deb",
      "line": 187,
      "relation": "association",
      "source": 11,
      "target": 49
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "8406fc047e85e8c5db7206a8a6e8ac87",
      "line": 157,
      "relation": "increases",
      "source": 8,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "ca8d37b6d25012a0189cf3251c0a28d8",
      "line": 188,
      "relation": "association",
      "source": 8,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "be4e725b939dae77646dd18c0b9de4e5",
      "line": 189,
      "relation": "association",
      "source": 8,
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "f40a104825d83aefc1d907edc9b972ca",
      "line": 190,
      "relation": "association",
      "source": 8,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "bfdaf9554658db11304b5ee8f2518833",
      "line": 191,
      "relation": "association",
      "source": 8,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "a25f8a6741ac94b0797d080de844549a",
      "line": 158,
      "relation": "increases",
      "source": 14,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "59a05abc1170f1ed0550175b379b7a41",
      "line": 192,
      "relation": "association",
      "source": 14,
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "d644d02e5bdee2f40dfb97f1597b9461",
      "line": 159,
      "relation": "increases",
      "source": 20,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "66979d98a5fdc0089564e0839ad5d219",
      "line": 193,
      "relation": "association",
      "source": 20,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "5c76c8aaf5bcd23376a780d64b6f30c0",
      "line": 194,
      "relation": "association",
      "source": 20,
      "target": 34
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "10e868d49fff0ca44778c22bc0669186",
      "line": 160,
      "relation": "increases",
      "source": 24,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "3182c6a802150d225801e4f683f0b9c6",
      "line": 195,
      "relation": "association",
      "source": 24,
      "target": 46
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "e67a09c7bb72006f98d0aec053fac09f",
      "line": 196,
      "relation": "association",
      "source": 24,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "a24e929978ff04922fb6c809b57dc510",
      "line": 161,
      "relation": "increases",
      "source": 12,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "b2050090141d211de1785a618bb88674",
      "line": 197,
      "relation": "association",
      "source": 12,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "b640cdfb8ca6de950da8a14ca1bafd44",
      "line": 162,
      "relation": "increases",
      "source": 9,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "93ffc0f8fb21ecc9d51ec1990b833416",
      "line": 198,
      "relation": "association",
      "source": 9,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "0f87c03da9edc55105526349dc26c51a",
      "line": 163,
      "relation": "increases",
      "source": 25,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "d67113021980bb0ba5e2eb894b85af6e",
      "line": 199,
      "relation": "association",
      "source": 25,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "7b95e2b509eb33ff7fa1b3fb6050dd72",
      "line": 164,
      "relation": "increases",
      "source": 21,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "9c3ad88912af6ab846d6305a155d03f1",
      "line": 200,
      "relation": "association",
      "source": 21,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "b239b3eb1d118a6a220cb52027d11cec",
      "line": 166,
      "relation": "decreases",
      "source": 3,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "005a4f9fc014bac59a04d2ec8a105efc",
      "line": 202,
      "relation": "association",
      "source": 3,
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "b05439cd3ff54418bfd756edcbc1708d",
      "line": 167,
      "relation": "decreases",
      "source": 15,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "0bc6c0482e9c23b5fb050f282d961b9f",
      "line": 203,
      "relation": "association",
      "source": 15,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "ab4dca1b9c2a3787f41314854dea1556",
      "line": 168,
      "relation": "decreases",
      "source": 4,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "86652000eaad08b368e1a1a1f9344ce5",
      "line": 204,
      "relation": "association",
      "source": 4,
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "a3c20a7ad2a3031ccecde4b4ef38e88d",
      "line": 169,
      "relation": "decreases",
      "source": 16,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "f3e5bf41636dbbc3d761325c52f707af",
      "line": 205,
      "relation": "association",
      "source": 16,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "8615ff07edc9ea248bab804b490bbb14",
      "line": 170,
      "relation": "decreases",
      "source": 23,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "92857c14361bd2ce730d277c84f77134",
      "line": 206,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 23,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "a646043206d748f7be2c9a3f3806b066",
      "line": 171,
      "relation": "decreases",
      "source": 5,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "fe5a53fc51059178d07d0013a76bf7b4",
      "line": 207,
      "relation": "association",
      "source": 5,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "c88cea2128bc968996b8d603c9c9ee7f",
      "line": 172,
      "relation": "decreases",
      "source": 7,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "8c9435dc8916058a39e1c1005995a733",
      "line": 208,
      "relation": "association",
      "source": 7,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "7f9fa23446f40eac558f7161eae3cd87",
      "line": 173,
      "relation": "decreases",
      "source": 29,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "67cb780cb9570ce42c8a99f56f71710e",
      "line": 209,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 29,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "d66696f2ea461423064748db939dd537",
      "line": 174,
      "relation": "decreases",
      "source": 10,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "694bb4945c512bcf1e2d35bea517598d",
      "line": 210,
      "relation": "association",
      "source": 10,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "b84dfc1d17f638a1a6c010056deadb0c",
      "line": 175,
      "relation": "decreases",
      "source": 19,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "2da451cb3bf3f40d1f07d5b333842772",
      "line": 211,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 19,
      "target": 31
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "36a28359c56a2c607db6ab293f6842d9",
      "line": 176,
      "relation": "decreases",
      "source": 18,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "a3b4cba7b26d8728fbcef61e1fb54868",
      "line": 212,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 18,
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "5dc0da612b3a5ca7c82aa2cefb278501",
      "line": 177,
      "relation": "decreases",
      "source": 27,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "8ecdccd51fa9a196a8e4d1eb23b2f8de",
      "line": 213,
      "relation": "association",
      "source": 27,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "bb225ee3b0b4485360c7fe584905e179",
      "line": 214,
      "relation": "association",
      "source": 27,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "5cf99281c6eebb7730880f3974421173",
      "line": 178,
      "relation": "decreases",
      "source": 13,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "db0644ffde2fdbd453e77327da19be3d",
      "line": 215,
      "relation": "association",
      "source": 13,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "d069b77fabfdc4ad2862da076de57846",
      "line": 179,
      "relation": "decreases",
      "source": 6,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "2b87528e14a9d4c8dd94a42000e495b3",
      "line": 216,
      "relation": "association",
      "source": 6,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "7fb31cf2b9306ce0bd843a2a9f6cc2ae",
      "line": 217,
      "relation": "association",
      "source": 6,
      "target": 58
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "31e2a8789935e8fbc419ce928e2caf16",
      "line": 180,
      "relation": "decreases",
      "source": 2,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "62fd7246f1997d0f54b3f1ccf9a7c5a5",
      "line": 218,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 2,
      "target": 31
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "e2b6cb5aaad088fcb3f491cf8bf64ed5",
      "line": 181,
      "relation": "decreases",
      "source": 22,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "5c4b9d73e95755835aa41e2c6359c81a",
      "line": 219,
      "relation": "association",
      "source": 22,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "655245db398896fc1152a7b560398720",
      "line": 182,
      "relation": "decreases",
      "source": 1,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "69f936465423928a3ca65ce54f908292",
      "line": 220,
      "relation": "association",
      "source": 1,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "3cc535cd7f6ef997dbf6426d4342dd8b",
      "line": 183,
      "relation": "decreases",
      "source": 17,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "852b7c6513799a14c2bf8875d3c4fe8a",
      "line": 221,
      "relation": "association",
      "source": 17,
      "target": 53
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "d9c14d6ce12ea1a56cbf86c6e367f176",
      "line": 222,
      "relation": "association",
      "source": 17,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "057c63db957f380970daecef177518f1",
      "line": 186,
      "relation": "association",
      "source": 48,
      "target": 11
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "d3e6cd0132df67719b9a3051816568e4",
      "line": 187,
      "relation": "association",
      "source": 49,
      "target": 11
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "eba7461b54398772b99df8b4c42fcc23",
      "line": 188,
      "relation": "association",
      "source": 32,
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "46b97562244f87c7d8d1d6f38184ccc8",
      "line": 198,
      "relation": "association",
      "source": 32,
      "target": 9
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "add2c77461d6ea63fbc15771fcede7c0",
      "line": 189,
      "relation": "association",
      "source": 33,
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "3eda358e0af76e2e66747ad62279232e",
      "line": 190,
      "relation": "association",
      "source": 42,
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "b1e5053132ab94539dbe7f35466298a3",
      "line": 191,
      "relation": "association",
      "source": 43,
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "4f9f4411d6b47d9f6c57091998596bca",
      "line": 192,
      "relation": "association",
      "source": 35,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "e9d2ab19c0c38cc617be0da19d727255",
      "line": 193,
      "relation": "association",
      "source": 37,
      "target": 20
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "25ed988cf8229862265b4f09abcd5454",
      "line": 194,
      "relation": "association",
      "source": 34,
      "target": 20
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "40cb7fb5362721ba7c005942497ea4f9",
      "line": 195,
      "relation": "association",
      "source": 46,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "e7549e5413a52af34141165cd646b92b",
      "line": 196,
      "relation": "association",
      "source": 47,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "c7aad91664eca2b35e4614e4a86ba322",
      "line": 197,
      "relation": "association",
      "source": 55,
      "target": 12
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "707571d2d344b3e1b24e41f3b1a4c041",
      "line": 199,
      "relation": "association",
      "source": 61,
      "target": 25
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "568cd0aeaf56847f79e11e4fff2abd35",
      "line": 200,
      "relation": "association",
      "source": 50,
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "a80b3979b00e9f7d7b7d76c4f89ed283",
      "line": 203,
      "relation": "association",
      "source": 57,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "933ae9f31b8ae681dffbf781e19975fc",
      "line": 215,
      "relation": "association",
      "source": 57,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "958db54630c9f84a25f25a82d7af0cc7",
      "line": 216,
      "relation": "association",
      "source": 57,
      "target": 6
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "b0a3a9498ef36de56cc54c7006e757c5",
      "line": 205,
      "relation": "association",
      "source": 38,
      "target": 16
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "dfbe6b9781626fb3b618ff3a39ccc14e",
      "line": 219,
      "relation": "association",
      "source": 41,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "b794e35054819a57f863583121a6cf68",
      "line": 210,
      "relation": "association",
      "source": 59,
      "target": 10
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "ee928deedd1fc6c91871e9d2363edc26",
      "line": 213,
      "relation": "association",
      "source": 56,
      "target": 27
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "e57700294d6ff2b5a86f1a7bdbc3d401",
      "line": 214,
      "relation": "association",
      "source": 51,
      "target": 27
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "e6024bab12baa01a932530e3e0bdab3e",
      "line": 217,
      "relation": "association",
      "source": 58,
      "target": 6
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "81a336bd674cab35bd78c73b5d383fb8",
      "line": 221,
      "relation": "association",
      "source": 53,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Denner P",
          "Fava E",
          "Kitanovic A",
          "Kurkowsky B",
          "Mandelkow E",
          "Möhl C",
          "Pickhardt M",
          "Tassoni M"
        ],
        "date": "2019-04-01",
        "db": "PubMed",
        "db_id": "30640040",
        "db_name": "Screening of a neuronal cell model of tau pathology for therapeutic compounds.",
        "first": "Pickhardt M",
        "journal": "Neurobiology of aging",
        "last": "Mandelkow E",
        "pages": "24-34",
        "volume": "76"
      },
      "evidence": "Tab. 1A-B: Summary of the Tau aggregation modulators (inhibitors = 18 (A), stimulators = 10 (B)) which show decrease / increase in the amount of ThS + cells without affecting the expression level of TauRD∆K compared to the compound untreated control. ",
      "key": "27fdfb6626069dbc2401414ad7a51a94",
      "line": 222,
      "relation": "association",
      "source": 45,
      "target": 17
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CONSO:\"Tau aggregates\")",
      "concept": {
        "name": "Tau aggregates",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "8e1da50e6008ffdd1b37825776666311"
    },
    {
      "bel": "a(PUBCHEM:10341154)",
      "concept": {
        "name": "10341154",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "d0fba515a5cdcc6c6b25a6be4b4dc2aa"
    },
    {
      "bel": "a(PUBCHEM:10435235)",
      "concept": {
        "name": "10435235",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "6188759816635812ddd8bbfb29a90939"
    },
    {
      "bel": "a(PUBCHEM:11154925)",
      "concept": {
        "name": "11154925",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "dcd69f909c2caa397af38cd2c003ca9d"
    },
    {
      "bel": "a(PUBCHEM:11234052)",
      "concept": {
        "name": "11234052",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "55e3310d76f2369e9c85abbf3edd946c"
    },
    {
      "bel": "a(PUBCHEM:11570805)",
      "concept": {
        "name": "11570805",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "d65778253b00f63e246e12ba140471bb"
    },
    {
      "bel": "a(PUBCHEM:11655119)",
      "concept": {
        "name": "11655119",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "2c765465ba289258a2d4bb6e8e69ce35"
    },
    {
      "bel": "a(PUBCHEM:156422)",
      "concept": {
        "name": "156422",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "d1ff32597f575c90f2a31e80f14051e0"
    },
    {
      "bel": "a(PUBCHEM:24756910)",
      "concept": {
        "name": "24756910",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "a83b63e88127e8e42e148c24b4343060"
    },
    {
      "bel": "a(PUBCHEM:2746)",
      "concept": {
        "name": "2746",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "101d131bccb94defe4feb3898a2fb116"
    },
    {
      "bel": "a(PUBCHEM:3033825)",
      "concept": {
        "name": "3033825",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "c7d8d38a9680c9e7082cecdec4b56121"
    },
    {
      "bel": "a(PUBCHEM:4261)",
      "concept": {
        "name": "4261",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "e95d9dea4107a7117cca633e747edc5d"
    },
    {
      "bel": "a(PUBCHEM:42640)",
      "concept": {
        "name": "42640",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "11c7a1dc3557f145b9fcf1ee315f0492"
    },
    {
      "bel": "a(PUBCHEM:447966)",
      "concept": {
        "name": "447966",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "c6aa01fc53eefe17ac710e1942d17695"
    },
    {
      "bel": "a(PUBCHEM:448537)",
      "concept": {
        "name": "448537",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "36b2d27d6ed1a1eb6aa303aa525a2d1b"
    },
    {
      "bel": "a(PUBCHEM:4521392)",
      "concept": {
        "name": "4521392",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "91581207d8153b4acbcd3ead66a6c357"
    },
    {
      "bel": "a(PUBCHEM:46209426)",
      "concept": {
        "name": "46209426",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "e389087635e6afe7da116d96de75a983"
    },
    {
      "bel": "a(PUBCHEM:4878)",
      "concept": {
        "name": "4878",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "4cee0d2b53f75fee3e610b077b94ff8b"
    },
    {
      "bel": "a(PUBCHEM:49806720)",
      "concept": {
        "name": "49806720",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "977fa9bbe7189881a6167d1724d649a2"
    },
    {
      "bel": "a(PUBCHEM:5311272)",
      "concept": {
        "name": "5311272",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "f1fa6a8751d05a83c607700e83788785"
    },
    {
      "bel": "a(PUBCHEM:5318517)",
      "concept": {
        "name": "5318517",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "ae387b4ff83579135438b9213e3ee085"
    },
    {
      "bel": "a(PUBCHEM:53340666)",
      "concept": {
        "name": "53340666",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "e6ef205ddc0f44f5c05a490db98b7877"
    },
    {
      "bel": "a(PUBCHEM:5833)",
      "concept": {
        "name": "5833",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "da2bb427aaf1dcc180081924c5d408d0"
    },
    {
      "bel": "a(PUBCHEM:6321424)",
      "concept": {
        "name": "6321424",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "99bf5d596145f7f183a5cf8f8466d628"
    },
    {
      "bel": "a(PUBCHEM:71295844)",
      "concept": {
        "name": "71295844",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "748f5753b45c067662450ed2cf95082d"
    },
    {
      "bel": "a(PUBCHEM:71729974)",
      "concept": {
        "name": "71729974",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "fb83bb209dc48d54aa1d307fd9f23ab9"
    },
    {
      "bel": "a(PUBCHEM:9804992)",
      "concept": {
        "name": "9804992",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "10e0e7a1d8525e1731e1356a59ae1593"
    },
    {
      "bel": "a(PUBCHEM:9839311)",
      "concept": {
        "name": "9839311",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "043974014b140841790833d2aa67c951"
    },
    {
      "bel": "a(PUBCHEM:9865515)",
      "concept": {
        "name": "9865515",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "80927084ea2db167556719a4b92f612e"
    },
    {
      "bel": "a(PUBCHEM:9880)",
      "concept": {
        "name": "9880",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "0bab63a21192a0f8887fdfc8b96515b2"
    },
    {
      "bel": "bp(GO:\"cell killing\")",
      "concept": {
        "name": "cell killing",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "d90ff2c504ac299738430c46896fc145"
    },
    {
      "bel": "p(FPLX:\"Gamma_secretase\")",
      "concept": {
        "name": "Gamma_secretase",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "e5aa42b4d5a7992fe30ecc5d01ae8dd8"
    },
    {
      "bel": "p(FPLX:\"HDAC_I\")",
      "concept": {
        "name": "HDAC_I",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "497b082718e3891c6c509c6a69c1992e"
    },
    {
      "bel": "p(FPLX:\"HDAC_II\")",
      "concept": {
        "name": "HDAC_II",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "a754e80a88a77ed8f0f9e09731677f09"
    },
    {
      "bel": "p(FPLX:Actin)",
      "concept": {
        "name": "Actin",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "70ff384ccc4427957df27ce1bb143da2"
    },
    {
      "bel": "p(FPLX:ESR)",
      "concept": {
        "name": "ESR",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "65e8f284f18d8ce1fd9eeae0e32eac2d"
    },
    {
      "bel": "p(FPLX:HDAC)",
      "concept": {
        "name": "HDAC",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "4963df953f4eaae0ba29f11bb988ab46"
    },
    {
      "bel": "p(FPLX:NFkappaB)",
      "concept": {
        "name": "NFkappaB",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "dafcbe06460fc2e93f4daf2113f37665"
    },
    {
      "bel": "p(FPLX:ROCK)",
      "concept": {
        "name": "ROCK",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "af4d155ac5c90c390760f1f4b7c7e420"
    },
    {
      "bel": "p(FPLX:TGFB)",
      "concept": {
        "name": "TGFB",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "911d7f50790453a94784d76bbeb4334a"
    },
    {
      "bel": "p(HGNC:ALK)",
      "concept": {
        "name": "ALK",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "798f3a64e529ffc86cdc2b4d2e11b325"
    },
    {
      "bel": "p(HGNC:AR)",
      "concept": {
        "name": "AR",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "4545a9fd93117463d368654c0cd789e3"
    },
    {
      "bel": "p(HGNC:EGFR)",
      "concept": {
        "name": "EGFR",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "2d0e5630f4a3b7a0fee65dbf00da20a5"
    },
    {
      "bel": "p(HGNC:ERBB2)",
      "concept": {
        "name": "ERBB2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "c5005a7bea6e8529684cdb8190000be3"
    },
    {
      "bel": "p(HGNC:FLT1)",
      "concept": {
        "name": "FLT1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "1e6f3f083b518598c191cce4942fd1b2"
    },
    {
      "bel": "p(HGNC:FYN)",
      "concept": {
        "name": "FYN",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "9aaa70667f9bfd5fd59c45422ea4c02c"
    },
    {
      "bel": "p(HGNC:GSK3A)",
      "concept": {
        "name": "GSK3A",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "ce7c231328d7b0e85ffd798a554023bd"
    },
    {
      "bel": "p(HGNC:GSK3B)",
      "concept": {
        "name": "GSK3B",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "8eaf29c9e491ff4e49619e77de92467c"
    },
    {
      "bel": "p(HGNC:HDAC1)",
      "concept": {
        "name": "HDAC1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "19e404c8c36931beb148345f3dae3052"
    },
    {
      "bel": "p(HGNC:HDAC3)",
      "concept": {
        "name": "HDAC3",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "2295758c8fd9e24078f3eb3e9fc6feea"
    },
    {
      "bel": "p(HGNC:HDAC6)",
      "concept": {
        "name": "HDAC6",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "8f10ead99d8970092c3980eb37bcfb3a"
    },
    {
      "bel": "p(HGNC:ICAM1)",
      "concept": {
        "name": "ICAM1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7f17c7170f0c093409f8f0505f248b50"
    },
    {
      "bel": "p(HGNC:KDR)",
      "concept": {
        "name": "KDR",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "dfadabebebc33f282a378ff9219fef94"
    },
    {
      "bel": "p(HGNC:LCK)",
      "concept": {
        "name": "LCK",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "b12ffdabce4924617b183ab3df9c996f"
    },
    {
      "bel": "p(HGNC:MAPK14)",
      "concept": {
        "name": "MAPK14",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "0c0476ae2f3918834fb6ae31829c9b8d"
    },
    {
      "bel": "p(HGNC:MDM4)",
      "concept": {
        "name": "MDM4",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "6ea70fc64d3e53bf69ff54e5f02d6545"
    },
    {
      "bel": "p(HGNC:SELE)",
      "concept": {
        "name": "SELE",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "33877b8a1a5bf4e57583ada4781fba7d"
    },
    {
      "bel": "p(HGNC:TGFBR1)",
      "concept": {
        "name": "TGFBR1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "54347535ff7c9720f25fada9dbfb5f85"
    },
    {
      "bel": "p(HGNC:TGFBR2)",
      "concept": {
        "name": "TGFBR2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "ecd80a47667baacbf3c5ab47563af97c"
    },
    {
      "bel": "p(HGNC:TNC)",
      "concept": {
        "name": "TNC",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "e297c62c060fa85f68c8de931771a5a0"
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"Chloride channel accessory\")",
      "concept": {
        "name": "Chloride channel accessory",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Protein",
      "id": "b92ef7958f55060b170f3c5bf92f7b4e"
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"Lysine demethylases\")",
      "concept": {
        "name": "Lysine demethylases",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Protein",
      "id": "96f55d31441380a3a009df4861baa889"
    }
  ]
}